- Home
- HIMX vs IMCR Comparison
HIMX vs IMCR Comparison
Compare HIMX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIMX
- IMCR
- Stock Information
- Founded
- HIMX 2001
- IMCR 2008
- Country
- HIMX Taiwan
- IMCR United Kingdom
- Employees
- HIMX N/A
- IMCR N/A
- Industry
- HIMX Semiconductors
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HIMX Technology
- IMCR Health Care
- Exchange
- HIMX Nasdaq
- IMCR Nasdaq
- Market Cap
- HIMX 1.7B
- IMCR 1.8B
- IPO Year
- HIMX 2006
- IMCR 2021
- Fundamental
- Price
- HIMX $7.42
- IMCR $32.88
- Analyst Decision
- HIMX Buy
- IMCR Buy
- Analyst Count
- HIMX 1
- IMCR 10
- Target Price
- HIMX $15.00
- IMCR $58.13
- AVG Volume (30 Days)
- HIMX 1.1M
- IMCR 325.8K
- Earning Date
- HIMX 08-07-2025
- IMCR 08-07-2025
- Dividend Yield
- HIMX 4.99%
- IMCR N/A
- EPS Growth
- HIMX N/A
- IMCR N/A
- EPS
- HIMX 0.42
- IMCR N/A
- Revenue
- HIMX $889,561,000.00
- IMCR $356,145,000.00
- Revenue This Year
- HIMX $2.50
- IMCR $27.43
- Revenue Next Year
- HIMX $9.42
- IMCR $8.64
- P/E Ratio
- HIMX $17.48
- IMCR N/A
- Revenue Growth
- HIMX N/A
- IMCR 26.78
- 52 Week Low
- HIMX $5.12
- IMCR $23.15
- 52 Week High
- HIMX $13.91
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- HIMX 28.81
- IMCR 46.01
- Support Level
- HIMX $7.28
- IMCR $31.02
- Resistance Level
- HIMX $7.55
- IMCR $33.73
- Average True Range (ATR)
- HIMX 0.27
- IMCR 1.54
- MACD
- HIMX -0.14
- IMCR -0.05
- Stochastic Oscillator
- HIMX 15.70
- IMCR 36.73
About HIMX Himax Technologies Inc.
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.